Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DXS InternationalSTU:7EE 39 EV-to-EBITDA is -5.35 as of Aug. 21, 2026. GuruFocus rates STU:7EE with a GF Score™ of 39/100 and a GF Value™ of €0.01. The stock has 5 warning signs investors should review. Among 512 Healthcare Providers & Services companies, DXS International ranks worse than 195312.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, DXS International's enterprise value is €0.79 Mil.
DXS International's EBITDA for the trailing twelve months (TTM) ended in Apr. 2025 was €-0.15 Mil. Therefore, DXS International's EV-to-EBITDA for today is -5.35.
The historical rank and industry rank for DXS International's EV-to-EBITDA or its related term are showing as below:
STU:7EE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.04 Med: 4.47 Max: 16.67
Current: -11
During the past 11 years, the highest EV-to-EBITDA of DXS International was 16.67. The lowest was -13.04. And the median was 4.47.
STU:7EE's EV-to-EBITDA is ranked worse than 100% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 10.6
vs STU:7EE: -11.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
DXS International (STU:7EE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DXS International's PE Ratio (TTM) for today is calculated as:
DXS International's share price for today is €0.011.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DXS International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2025 was €-0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for DXS International's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7EE vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, DXS International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DXS International EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DXS International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where DXS International's EV-to-EBITDA falls into.
DXS International's current Enterprise Value is €0.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DXS International's EBITDA for the trailing twelve months (TTM) ended in Apr. 2025 was €-0.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DXS International (STU:7EE) has a EV-to-EBITDA of -5.35 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DXS International. According to the industry distribution chart, DXS International ranks #999999 out of 512 companies in the Healthcare Providers & Services industry.
Is DXS International's EV-to-EBITDA too high?
DXS International's current EV-to-EBITDA is -5.35. Based on the distribution chart, DXS International ranks #999999 out of 512 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DXS International has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does DXS International's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DXS International ranks #999999 out of 512 companies for EV-to-EBITDA. This places DXS International in the lower half of its industry. The industry median EV-to-EBITDA is 10.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.60, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on DXS International. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DXS International's current EV-to-EBITDA is -5.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
DXS International (STU:7EE) has a current EV-to-EBITDA of -5.35. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 10% above its estimated fair value. The current EV-to-EBITDA is -5.35. DXS International's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For DXS International (STU:7EE), the current EV-to-EBITDA is -5.35 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DXS International (STU:7EE) Overvalued in 2026?
Based on GuruFocus' analysis, DXS International stock appears to be overvalued.
The current stock price of €0.01 is trading 10% above its estimated GF Value™ of €0.01.
Key valuation signals for STU:7EE:
EV-to-EBITDA: -5.35
GF Value™: €0.01 vs. price of €0.01 (10% above fair value)
No single metric tells the full story. See the STU:7EE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
39GF Score
Get the complete analysis for STU:7EE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7EE has been successfully added to your 
